|

Tezepelumab Clinical Trials

6 actively recruiting trials across 4 locations

▼ -1 trial since June 2026

Also known as: MEDI9929 and AMG157, TEZSPIRE

Pipeline

Phase 2: 1Phase 3: 4

Top Sponsors

  • AstraZeneca5
  • Asger Sverrild1

Indications

  • Asthma3
  • COPD3
  • Chronic Obstructive Pulmonary Disease (COPD)2
  • COPD Bronchitis1
  • Airway Disease1

Other2 trials

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
Phase 2
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Phase 3

Cullman, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Research Site

Phase 3

Foley, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Research Site

Phase 3

Montgomery, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Research Site

Phase 3

Wilmington, Delaware1 trial

Tezspire Cardiac Events PASS

Healthcare Integrated Research Database (HIRD)

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.